In Hemophilia Α Plasma Treated with Emicizumab, Factor IXa in Activated Prothrombin Complex Concentrates Is the Dominant Contributor to Enhanced Thrombin Generation
نویسندگان
چکیده
منابع مشابه
Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran
Abstract Nowadays, bypassing agents such as recombinant activated factor VII (rFVIIa) and activated prothrombin complex concentrates (aPCC) are used to treat bleeding episodes in the Hemophilia patients with inhibitors. AryoSeven® is an Iranian biogeneric rFVIIa with homogeneity of efficacy and the nature to NovoSeven in a comparative trial. The current clinical trial aimed to evaluate the cost...
متن کاملCost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran
Abstract Nowadays, bypassing agents such as recombinant activated factor VII (rFVIIa) and activated prothrombin complex concentrates (aPCC) are used to treat bleeding episodes in the Hemophilia patients with inhibitors. AryoSeven® is an Iranian biogeneric rFVIIa with homogeneity of efficacy and the nature to NovoSeven in a comparative trial. The current clinical trial aimed to evaluate the cost...
متن کاملcost-effectiveness analysis of biogeneric recombinant activated factor vii (aryoseven™) and activated prothrombin complex concentrates (feiba™) to treat hemophilia a patients with inhibitors in iran
abstract nowadays, bypassing agents such as recombinant activated factor vii (rfviia) and activated prothrombin complex concentrates (apcc) are used to treat bleeding episodes in the hemophilia patients with inhibitors. aryoseven® is an iranian biogeneric rfviia with homogeneity of efficacy and the nature to novoseven in a comparative trial. the current clinical trial aimed to evaluate the cost...
متن کامل6 Factor VIII Concentrates, Factor VIII/von Willebrand Factor Concentrates, Factor IX Concentrates, Activated Prothrombin Complex Concentrates
6.5 Range of Application, Dosage, Mode of Administration 6.5.1 General Information 6.5.2 Indications for Replacement Therapy Using Factor Concentrates 6.5.3 Dosage, Mode of Administration 6.5.3.1 Replacement in Children with Hemophilia A, B or von Willebrand Syndrome 6.5.3.2 Replacement in Adults with Hemophilia A, B or von Willebrand Syndrome 6.5.3.3 Indications and Recommended Doses for Treat...
متن کامل6 Factor VIII Concentrates, Factor VIII/von Willebrand Factor Concentrates, Factor IX Concentrates, Activated Prothrombin Complex Concentrates.
6.5 Range of Application, Dosage, Mode of Administration 6.5.1 General Information 6.5.2 Indications for Replacement Therapy Using Factor Concentrates 6.5.3 Dosage, Mode of Administration 6.5.3.1 Replacement in Children with Hemophilia A, B or von Willebrand Syndrome 6.5.3.2 Replacement in Adults with Hemophilia A, B or von Willebrand Syndrome 6.5.3.3 Indications and Recommended Doses for Treat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 2020
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood-2020-139586